| Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer WD Foulkes, IM Stefansson, PO Chappuis, LR Bégin, JR Goffin, N Wong, ... Journal of the national cancer institute 95 (19), 1482-1485, 2003 | 1304 | 2003 |
| Probability of cancer in pulmonary nodules detected on first screening CT A McWilliams, MC Tammemagi, JR Mayo, H Roberts, G Liu, K Soghrati, ... New England journal of medicine 369 (10), 910-919, 2013 | 1295 | 2013 |
| The prognostic implication of the basal-like (cyclin Ehigh/p27low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer WD Foulkes, JS Brunet, IM Stefansson, O Straume, PO Chappuis, ... Cancer research 64 (3), 830-835, 2004 | 516 | 2004 |
| A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment ME Robson, PO Chappuis, J Satagopan, N Wong, J Boyd, JR Goffin, ... Breast Cancer Research 6, 1-10, 2003 | 355 | 2003 |
| First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review J Goffin, C Lacchetti, PM Ellis, YC Ung, WK Evans Journal of Thoracic Oncology 5 (2), 260-274, 2010 | 271 | 2010 |
| Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian Cancer Trials Group CO. 26 Study EX Chen, DJ Jonker, JM Loree, HF Kennecke, SR Berry, F Couture, ... JAMA oncology 6 (6), 831-838, 2020 | 267 | 2020 |
| Survival of patients with non-small-cell lung cancer after a diagnosis of brain metastases A Ali, JR Goffin, A Arnold, PM Ellis Current Oncology 20 (4), 300-306, 2013 | 267 | 2013 |
| Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study MC Tammemagi, H Schmidt, S Martel, A McWilliams, JR Goffin, ... The lancet oncology 18 (11), 1523-1531, 2017 | 204 | 2017 |
| The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency S Cressman, SJ Peacock, MC Tammemägi, WK Evans, NB Leighl, ... Journal of Thoracic Oncology 12 (8), 1210-1222, 2017 | 139 | 2017 |
| Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10‐Year follow‐up data JR Goffin, PO Chappuis, LR Bégin, N Wong, JS Brunet, N Hamel, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 134 | 2003 |
| Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers O Straume, PO Chappuis, HB Salvesen, OJ Halvorsen, SA Haukaas, ... Cancer Research 62 (23), 6808-6811, 2002 | 133 | 2002 |
| Cost-effectiveness of lung cancer screening in Canada JR Goffin, WM Flanagan, AB Miller, NR Fitzgerald, S Memon, MC Wolfson, ... JAMA oncology 1 (6), 807-813, 2015 | 121 | 2015 |
| Epidermal growth factor receptor: pathway, therapies, and pipeline JR Goffin, K Zbuk Clinical therapeutics 35 (9), 1282-1303, 2013 | 117 | 2013 |
| Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval J Goffin, S Baral, D Tu, D Nomikos, L Seymour Clinical cancer research 11 (16), 5928-5934, 2005 | 104 | 2005 |
| Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group SA Laurie, A Gupta, Q Chu, CW Lee, W Morzycki, R Feld, AH Foo, J Seely, ... Journal of Thoracic Oncology 6 (11), 1950-1954, 2011 | 79 | 2011 |
| Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment PO Chappuis, E Donato, JR Goffin, N Wong, LR Begin, LR Kapusta, ... Annals of oncology 16 (5), 735-742, 2005 | 71 | 2005 |
| Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness JR Goffin, WM Flanagan, AB Miller, NR Fitzgerald, S Memon, MC Wolfson, ... Lung Cancer 101, 98-103, 2016 | 66 | 2016 |
| Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-Based Care. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer … J Goffin, C Lacchetti, PM Ellis, YC Ung, WK Evans J Thorac Oncol 5 (2), 260-74, 2010 | 64 | 2010 |
| CCTG CO. 26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced … EX Chen, DJ Jonker, HF Kennecke, SR Berry, F Couture, CE Ahmad, ... Journal of Clinical Oncology 37 (4_suppl), 481-481, 2019 | 57 | 2019 |
| Low prevalence of high-grade lesions detected with autofluorescence bronchoscopy in the setting of lung cancer screening in the pan-canadian lung cancer screening study A Tremblay, N Taghizadeh, AM McWilliams, P MacEachern, DR Stather, ... Chest 150 (5), 1015-1022, 2016 | 56 | 2016 |
